Evommune hosts webcast on MRGPRX2 inhibition for migraine treatment

Evommune, Inc.

Presentation reviews migraine treatment landscape and potential role of MRGPRX2 inhibition.
No new clinical data, financial results, or regulatory milestones disclosed.
Webcast replay available on company IR website.

item 7.01 item 9.01

Evommune, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-152864

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.